Skip Nav Destination
Issues
1 April 2016
-
Cover Image
Cover Image
Cancer risk in premalignant diseases, such as Barrett’s Esophagus or Inflammatory Bowel Disease, is frequently over-diagnosed and leads to the over-treatment of patients. These problems are a consequence of the lack of biomarkers that are able to accurately determine cancer risk in premalignant disease. A biomarker is an assayable property of the disease that correlates with the risk of cancer development; examples of potential biomarkers include the proportion of proliferating cells in a biopsy or the amount of a secreted protein. The study by Dhawan and colleagues (page 283) sort to address a major challenge to biomarker development: how to select the best candidate biomarker from the near-limitless list of candidates. The authors did this by constructing a computational model of cancer development, and using the computer to perform a wide-ranging in silico search of biomarker candidates. The cover image shows a snapshot from the simulation: each colored square represents a cell, and the color of the square indicates how many advantageous (driver) mutations that cell has acquired (red=many, dark blue=few). At each step in the simulation, a cell is chosen to replace a neighbor at a rate proportional to the differential number of advantageous mutations between the two cells. This process leads to ‘clonal expansions’ of patches of neighboring cells with similar genotypes (patches of identically colored cells in the image). The study illustrates how a computational model can provide a high-throughput and low-cost platform for the preliminary assessment of candidates biomarkers, and in so doing diminish the empirical constraints on biomarker development. - PDF Icon PDF LinkTable of Contents
ISSN 1940-6207
EISSN 1940-6215
Issue Sections
Research Articles
Whole-Genome Sequencing of Salivary Gland Adenoid Cystic Carcinoma
Eleni M. Rettig; C. Conover Talbot, Jr; Mark Sausen; Sian Jones; Justin A. Bishop; Laura D. Wood; Collin Tokheim; Noushin Niknafs; Rachel Karchin; Elana J. Fertig; Sarah J. Wheelan; Luigi Marchionni; Michael Considine; Shizhang Ling; Carole Fakhry; Nickolas Papadopoulos; Kenneth W. Kinzler; Bert Vogelstein; Patrick K. Ha; Nishant Agrawal
Influence of Obesity on Breast Density Reduction by Omega-3 Fatty Acids: Evidence from a Randomized Clinical Trial
Narinder Sandhu; Susann E. Schetter; Jason Liao; Terryl J. Hartman; John P. Richie; John McGinley; Henry J. Thompson; Bogdan Prokopczyk; Cynthia DuBrock; Carina Signori; Christopher Hamilton; Ana Calcagnotto; Neil Trushin; Cesar Aliaga; Laurence M. Demers; Karam El-Bayoumy; Andrea Manni
Author Choice
Hepatic Premalignant Alterations Triggered by Human Nephrotoxin Aristolochic Acid I in Canines
Ke Jin; Kun-kai Su; Tong Li; Xia-qing Zhu; Qi Wang; Ren-shan Ge; Zong-fu Pan; Bo-wen Wu; Li-jun Ge; Yi-han Zhang; Yi-fan Wang; Guo-fang Shen; Dan-yan Zhu; Chun-sheng Xiang; Lan-juan Li; Yi-jia Lou
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.